Sentence 1: Such 92 allowed and issued applications include the following: 2 issued U.S. patents directed to a pharmaceutical composition of Vascepa in a capsule that have terms that expire in 2020 and 2030, respectively; 1 issued U.S. patent covering a composition containing highly pure EPA that expires in 2021; 49 U.S. patents covering or related to the use of Vascepa in either the MARINE or ANCHOR populations that have terms that expire in 2030 or later; 14 U.S. patents covering or related to the use of Vascepa in the REDUCE-IT population with terms expiring in 2033 or later; 1 additional US patent directed to a pharmaceutical composition comprised of free fatty acids with a term that expires in 2030; 4 additional patents related to the use of a pharmaceutical composition comprised of free fatty acids to treat the ANCHOR patient population with a term that expires in 2030 or later; 2 additional patents related to the use of a pharmaceutical composition comprised of free fatty acids to treat the MARINE patient population with a term that expires in 2030; 3 additional patents related to the use of a pharmaceutical composition comprised of free fatty acids to treat the REDUCE-IT population expiring 2033; 3 additional patent related to a pharmaceutical composition comprised of free fatty acids and uses thereof to treat both the MARINE and ANCHOR patient populations with a term that expires in 2030; 1 additional patent related to the use of a pharmaceutical composition comprised of re-esterified EPA triglyceride to treat the REDUCE-IT population expiring 2033; 3 additional patents related to a formulation of EPA/DHA and uses thereof with a term that expires in 2030; 2 additional patents related to the use of Vascepa to treat obesity with a term that expires in 2034; 3 additional patents covering a pharmaceutical composition comprised of EPA and a hydroxyl compound with a term that expires in 2034; and 4 additional patents covering a new combination therapy comprised of EPA and another drug.
Sentence 2: Such 79 allowed and issued applications include the following: 2 issued U.S. patents directed to a pharmaceutical composition of Vascepa in a capsule that have terms that expire in 2020 and 2030, respectively; 1 issued U.S. patent covering a composition containing highly pure EPA that expires in 2021; 43 U.S. patents covering or related to the use of Vascepa in either the MARINE or ANCHOR populations that have terms that expire in 2030 or later; 11 U.S. patents covering or related to the use of Vascepa in the REDUCE-IT population with terms expiring in 2033 or later; 4 additional patents related to the use of a pharmaceutical composition comprised of free fatty acids to treat the ANCHOR patient population with a term that expires in 2030 or later; 2 additional patents related to the use of a pharmaceutical composition comprised of free fatty acids to treat the MARINE patient population with a term that expires in 2030; 3 additional patents related to the use of a pharmaceutical composition comprised of free fatty acids to treat the REDUCE-IT population expiring 2033; 1 additional patent related to a pharmaceutical composition comprised of free fatty acids and uses thereof to treat both the MARINE and ANCHOR patient populations with a term that expires in 2030; 1 additional patent related to the use of a pharmaceutical composition comprised of re-esterified EPA triglyceride to treat the REDUCE-IT population expiring 2033; 3 additional patents related to a formulation of EPA/DHA and uses thereof with a term that expires in 2030; 2 additional patents related to the use of Vascepa to treat obesity with a term that expires in 2034; 2 additional patents covering a pharmaceutical composition comprised of EPA and a hydroxyl compound with a term that expires in 2034; and 4 additional patents covering a new combination therapy comprised of EPA and another drug.
Semantic similarity (0-5): 3